figure
posted on 2023-06-13, 14:20 authored by Kazunori Aoki, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi, Etsuko Fujii, Takashi Nishizawa, Hironori Fukuda, Kana Ohashi, Kosuke Arai, Yukihiro Mizoguchi, Yukihiro Yoshida, Shun-ichi Watanabe, Makiko Yamashita, Shigehisa Kitano, Hiromi Sakamoto, Yuki Nagata, Risa Mitsumori, Kouichi Ozaki, Shumpei Niida, Yae Kanai, Akiyoshi Hirayama, Tomoyoshi Soga, Toru Maruyama, Keisuke Tsukada, Nami Yabuki, Mei Shimada, Takehisa Kitazawa, Osamu Natori, Noriaki Sawada, Atsuhiko Kato, Teruhiko Yoshida, Kazuki Yasuda, Hideaki Mizuno, Hiroyuki Tsunoda, Atsushi Ochiai Patient outcomes in immune subtypes. A and B, Kaplan–Meier EFS curves for subtypes of LUAD (A) and LUSQ (B). P values were calculated by multivariate Cox regression. C and D, Relationships of cell density (left) with �45 (right) for each immune cell type infiltrated in tumors to patient prognosis in LUAD (C) and LUSQ (D). Z-scores from Cox proportional hazards analysis are plotted; in the plots, red dots indicate P ≤ 0.05. E and F, Differences in histopathologic findings for immune subtypes of LUAD (E) and LUS (F). The P values determined using Fisher exact test w are plotted; in the plots, red circles indicate P ≤ 0.05 and filled red circles indicate Holm-adjusted P ≤ 0.2. G and H, Frequencies of each classification in immune subtypes in LUAD (G) and LUSQ (H). Numbers of patients are indicated in the bar segments.
Funding
Japan Agency for Medical Research and Development (AMED)
National Cancer Center Japan (NCC)
MEXT | Japan Society for the Promotion of Science (JSPS)
History
ARTICLE ABSTRACT
The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.
